Sony Tuteja

The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i>, <i>ABCG2</i>, and <i>CYP2C9</i> genotypes and Statin‐Associated Musculoskeletal Symptoms

Rhonda M. Cooper‐DeHoff, Mikko Niemi, Laura B. Ramsey et al. · Clinical Pharmacology & Therapeutics · 2022 · 296 citations · Full text

Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users

Catherine Chanfreau‐Coffinier, Leland E. Hull, Julie A. Lynch et al. · JAMA Network Open · 2019 · 162 citations · Full text

Genetic Epidemiology, Pharmacotherapy, Genetic Medicine +22

Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotype‐Guided Antiplatelet Therapy

Philip E. Empey, James M. Stevenson, Sony Tuteja et al. · Clinical Pharmacology & Therapeutics · 2017 · 124 citations · Full text

Patient Selection, Pharmacotherapy, Thrombosis +17

Trends in Platelet Adenosine Diphosphate P2Y₁₂ Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016

Elias J. Dayoub, Matthew Seigerman, Sony Tuteja et al. · JAMA Internal Medicine · 2018 · 115 citations · Full text

THE EFFECT OF GUT METABOLISM ON TACROLIMUS BIOAVAILABILITY IN RENALTRANSPLANT RECIPIENTS1,2

Sony Tuteja, Rita R. Alloway, Julie A. Johnson et al. · Transplantation · 2001 · 111 citations